IndonesiaTuberculosis profile
Population  2014 254 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 100 (66–150) 41 (26–59)
Mortality (HIV+TB only) 22 (13–32) 8.5 (5.2–13)
Prevalence  (includes HIV+TB) 1 600 (1 300–2 000) 647 (513–797)
Incidence  (includes HIV+TB) 1 000 (700–1 400) 399 (274–546)
Incidence (HIV+TB only) 63 (41–90) 25 (16–36)
         
Case detection, all forms (%) 32 (23–46)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.9 (1.4–2.5) 12 (8.1–17)
MDR-TB cases among notified pulmonary
TB cases
5 600 (4 200–7 400) 1 100 (770–1 600)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 193 321   6 449
Pulmonary, clinically diagnosed 101 991   1 391
Extrapulmonary 19 653   1
       
Total new and relapse 322 806    
Previously treated, excluding relapses 1 733    
Total cases notified 324 539    
Among 322 806 new and relapse cases:
23 170 (7%) cases aged under 15 years; male:female ratio: 1.4
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 1 058 (<1%) 8 445 (88%) 9 503
Laboratory-confirmed RR-/MDR-TB cases     1 812
Patients started on MDR-TB treatment ***     1 284
TB/HIV 2014 Number (%)
TB patients with known HIV status 15 074 (5)
HIV-positive TB patients 2 355 (16)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 963 (41)
HIV-positive TB patients on antiretroviral therapy (ART) 624 (26)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (88) 325 582
Previously treated cases, excluding relapse, registered in 2013 (64) 1 521
HIV-positive TB cases, all types, registered in 2013 (49) 2 438
RR-/MDR-TB cases started on second-line treatment in 2012 (54) 432
XDR-TB cases started on second-line treatment in 2012 (64) 11
Laboratories 2014  
Smear (per 100 000 population) 2.2
Culture (per 5 million population) 0.4
Drug susceptibility testing (per 5 million population) 0.3
Sites performing Xpert MTB/RIF 41
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 133
% Funded domestically 13%
% Funded internationally 21%
% Unfunded 66%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-09-30 Data: www.who.int/tb/data